Raymond James Financial
PTGX icon

Raymond James Financial’s Protagonist Therapeutics PTGX Stock Holding History

Raymond James Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6M Sell
168,270
-9,091
-5% -$950K 0.01% 1538
2026
Q1 		$17.8M Sell
177,361
-4,142
-2% -$367K 0.01% 1561
2025
Q4 		$15.8M Sell
181,503
-112,793
-38% -$9.23M ﹤0.01% 1606
2025
Q3 		$19.6M Sell
294,296
-17,690
-6% -$1.01M 0.01% 1427
2025
Q2 		$17.2M Buy
311,986
+13,159
+4% +$632K 0.01% 1482
2025
Q1 		$14.5M Sell
298,827
-4,486
-1% -$188K 0.01% 1536
2024
Q4 		$11.7M Buy
+303,313
New +$13.2M ﹤0.01% 1724

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Raymond James Financial's PTGX Position: Q2 2026 in Review

Raymond James Financial reduced its Protagonist Therapeutics (PTGX) stake by 5.1% in Q2 2026, selling an estimated $950K and leaving 168,270 shares worth $20.6M. The position accounts for 0.01% of the portfolio, ranked #1538.

Raymond James Financial first reported a position in PTGX in Q4 2024 and has held it in 7 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Raymond James Financial held 168,270 shares of Protagonist Therapeutics worth $20.6M as of Q2 2026.
  • Raymond James Financial sold 9,091 Protagonist Therapeutics shares in Q2 2026, an estimated $950K.
  • Protagonist Therapeutics made up 0.01% of Raymond James Financial's portfolio in Q2 2026, its #1538 holding.
  • Raymond James Financial first reported a position in Protagonist Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.